1. Home
  2. BZFD vs TVRD Comparison

BZFD vs TVRD Comparison

Compare BZFD & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BuzzFeed Inc.

BZFD

BuzzFeed Inc.

N/A

Current Price

$0.79

Market Cap

33.5M

ML Signal

N/A

TVRD

Tvardi Therapeutics Inc.

N/A

Current Price

$3.95

Market Cap

34.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BZFD
TVRD
Founded
2006
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Movies/Entertainment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.5M
34.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BZFD
TVRD
Price
$0.79
$3.95
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$51.67
AVG Volume (30 Days)
184.7K
39.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$0.51
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$292.15
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.74
$3.50
52 Week High
$2.68
$43.65

Technical Indicators

Market Signals
Indicator
BZFD
TVRD
Relative Strength Index (RSI) 44.71 47.62
Support Level $0.77 $3.81
Resistance Level $0.84 $4.39
Average True Range (ATR) 0.04 0.23
MACD 0.01 0.04
Stochastic Oscillator 57.39 54.93

Price Performance

Historical Comparison
BZFD
TVRD

About BZFD BuzzFeed Inc.

BuzzFeed Inc is a tech-powered, diversified media company that reaches hundreds of millions globally through its cross-platform news and entertainment network. The company produces articles, lists, quizzes, videos, and original series; lifestyle content through brands including Tasty, social food network; original reporting and investigative journalism through BuzzFeed News and HuffPost; an industry- affiliate business, strategic partnerships, licensing and product development through BuzzFeed Commerce; and original productions across broadcast, cable, SVOD, film and digital platforms for BuzzFeed Studios.

About TVRD Tvardi Therapeutics Inc.

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Share on Social Networks: